Tagged with A

Boryung Pharmaceutical Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you tell us, as the founder, about this notable achievement? Boryung just celebrated in 2007 its 50th anniversary, since it was…

Pfizer South Korea Previous to your current position as President of Pfizer Korea since 2004, you had been in the country between 1989 and 1993 as sales and marketing director. How different are things in Korea’s pharmaceutical industry 15 years since you first left it? South Korea has evolved dramatically over the last…

Merck South Korea You have been in South Korea for several months, following some time as Merck’s President in Pakistan. In your opinion, what do you find as the most interesting aspects of the Korean pharmaceutical market so far? South Korea is the 12th largest pharmaceutical market in the world, making it a…

Anugerah Corporation The development of the Local Pharmaceutical industry companies has gone through rough times, competing from the very beginning with MNCs and going through the economic shock in the 90’s. In this period while many companies couldn’t cope with the market competition, Anguerah Corporation succeeded in positioning itself as one of…

Euticals group After a long experience at BMS, you are since 2002 at the head of Euticals- a well established group consisting of four entities (Euticals, Ambrosia, Prochisa and Pro.Bio.Sint), each of them developing and producing Active Pharmaceutical Ingredients (APIs) by different processes. To begin, could you give us an overview of…

Korea National Enterprise for Clinical Trials Korea had a late start, but is now one of the global hot spots for clinical trials. How would you sum up and explain this quick evolution? Clinical trials in Korea began in the 1990s, but at that time they were limited to either local studies for domestically developed compounds…

Daiichi Sankyo Italy When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in this 5 years period. What have been the main guidelines of the Italian operations? Daiichi Sankyo Italy’s ability to brilliantly…

Assobiotec Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report dedicated to biotechnologies in Italy, the sector’s turnover reaches approximately 5 billion Euros and represents 0,6% of the global Italian…

International Pharmaceutical Manufacturing Gr Although Indonesia in the last ten years had the second highest growth in ASIA in terms of drugs’ production and consumption, the market share of research based companies has dropped from 50% to 25%. What have been the main drivers leading to the current scenario? The share of international companies…

Parexel International Italy Over more than 25 years, PAREXEL has expanded its global footprint through a combination of organic growth, alliances, and acquisitions. What was the rationale behind entering Italy in 1995 and which opportunities does the local environment provide to the group? The high number of clinical trials conducted in Italy every…

Mersifarma The Indonesian pharmaceutical market has gone through a series of developing phases which have ultimately led the domestic industry to gain the majority of the market share. In this respect what has been Mersi contribution to the development of the Indonesian pharmaceutical industry? My original vision for the company was…

Bausch & Lomb Germany With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities that no other company could thanks to its own transformations and special needs. Since Bausch&Lomb changed ownership in 2007, our…